Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
:NBY
Holding NBY?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.24Last Year’s EPS
-46.55Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2018
|% Change Since: -1.43%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook, with strong growth and efficiency improvements in the eyecare segment, but challenges in overall revenue and net loss due to declines in wound care sales and low cash reserves.Company Guidance
During the NovaBay Pharmaceuticals Q2 2024 earnings call, the company reported a strong performance in its eyecare segment, with sales of eyecare products reaching $4.8 million for the first half of the year. They are on track to meet their annual target of $10 million in eyecare sales. The company has successfully reduced sales and marketing expenses by 13% year-over-year while achieving an 8% increase in eyecare revenue for Q2 2024, primarily through online OTC channels. Subscribe & Save customers on Amazon, their largest sales channel, grew by 16% in the first half of 2024, contributing to approximately 24% of online Avenova revenue. The gross margin improved to 66% in Q2 2024 from 49% in the prior year due to a shift towards higher-margin eyecare products. NovaBay's strategic focus remains on efficient growth within the U.S. dry eye market, anticipated to exceed $4.8 billion by 2030.Eyecare Business Growth
Sales from eyecare products reached $4.8 million for the first half of 2024, showing growth in the eyecare segment driven by Avenova branded products.
Increase in Subscription Customers
The number of Avenova Subscribe & Save customers on Amazon increased by 123% since the beginning of 2022, 64% since the beginning of 2023, and 16% for the first 6 months of 2024.
Record Prime Day Sales
Avenova sales were 17% higher than Prime Day 2023 and 40% higher than Prime Day 2022.
Gross Margin Improvement
Gross margin on net product revenue for Q2 2024 was 66%, compared with 49% for Q2 2023, due to increased sales of higher-margin eyecare products.
Reduction in Marketing Expenses
Sales and marketing expenses for Q2 2024 declined 13% from the prior year, highlighting improved cost efficiency.
---
NBY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NBY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $0.70 | $0.69 | -1.43% |
| Aug 13, 2024 | $0.48 | $0.46 | -4.17% |
| May 09, 2024 | $3.12 | $2.81 | -9.94% |
| Mar 26, 2024 | $4.86 | $3.89 | -19.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novabay Pharmaceuticals (NBY) report earnings?
Novabay Pharmaceuticals (NBY) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Novabay Pharmaceuticals (NBY) earnings time?
Novabay Pharmaceuticals (NBY) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NBY EPS forecast?
NBY EPS forecast for the fiscal quarter 2024 (Q4) is -0.24.
---